Investigating lipocalin-2 to prevent weight loss and cognitive decline in cancer patients
PQ6: Lipocalin-2 as a therapeutic target for prevention of cancer cachexia
This study is looking at how cancer affects the body by causing a molecule called lipocalin-2 to be produced, which might lead to loss of appetite and trouble thinking, and it aims to find ways to help cancer patients who are experiencing severe weight loss and muscle loss.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11061244 on NIH RePORTER |
What this research studies
This research focuses on understanding how cancer triggers the production of a molecule called lipocalin-2, which may lead to loss of appetite and cognitive decline in patients. By exploring the mechanisms of neuroinflammation associated with cancer, the study aims to identify potential therapeutic targets to combat cachexia, a condition characterized by severe weight loss and muscle wasting. The research employs a combination of laboratory experiments and collaborations to unravel these complex interactions, ultimately seeking to improve the quality of life for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients experiencing cachexia, appetite loss, or cognitive decline.
Not a fit: Patients with non-cancer-related conditions or those not experiencing cachexia or cognitive issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent weight loss and cognitive decline in cancer patients, enhancing their overall quality of life.
How similar studies have performed: While the specific approach of targeting lipocalin-2 is novel, similar research has shown promise in understanding and addressing cachexia in cancer patients.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Zimmers, Teresa a — Oregon Health & Science University
- Study coordinator: Zimmers, Teresa a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.